Roivant receives bad news — and so does SoftBank

 Last month, SoftBank, through its massive Vision Fund, led the single biggest private financing round for a healthcare company ever — funneling $1.1 billion into the drug holding outfit Roivant Sciences. Today, the Japanese conglomerate might be regretting that decision. Read More


This entry has 0 replies

Comments are closed.